<DOC>
	<DOCNO>NCT00003546</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness gemcitabine plus radiation therapy treat patient pancreatic cancer remove surgically .</brief_summary>
	<brief_title>Gemcitabine Plus Radiation Therapy Treating Patients With Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate time progression overall survival patient locoregional adenocarcinoma pancreas treat gemcitabine combine radiation therapy . II . Estimate biomarker response regimen evaluation circulate CA19-9 level correlate response survival patient population . OUTLINE : Patients receive radiation therapy 5 day per week 5 1/2 week gemcitabine IV 30 minute great 2 hour prior radiation therapy twice weekly . This combination radiation therapy chemotherapy follow 2 week rest . Patients stable respond disease receive high dose gemcitabine IV 30 minute weekly 3 week follow 1 week rest . This 4 week course repeat 3 time total 16 week gemcitabine therapy alone . Patients follow every 2 month first year every 3 month next 2 year disease progression . Upon documentation disease progression , patient follow every 3 month survival secondary malignancy . PROJECTED ACCRUAL : A total 40 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Locoregional amenable surgery base 1 follow : Size pancreatic tumor great 5 cm Lymph nod bulky , great 2 cm , within radiation port Vascular involvement impingement major vessel ( e.g. , superior mesenteric artery , superior mesenteric vein , portal vein , hepatic artery ) Involvement colon ( head lesion ) involvement adrenal , kidney , colon ( tail lesion ) Patients must register begin treatment within 42 day surgical stag No metastatic disease nodal disease outside radiation port document CT scan MRI chest xray PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Albumin great 3 g/dL Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL Calcium normal Other : No prior concurrent malignancy within past 5 year except inactive nonmelanoma skin cancer , carcinoma situ cervix , curatively treat cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy carcinoma pancreas Chemotherapy : No prior chemotherapy carcinoma pancreas No concurrent chemotherapy Endocrine therapy : No prior endocrine therapy carcinoma pancreas No concurrent hormone therapy ( except nondiseaserelated condition ) Radiotherapy : No prior radiation therapy carcinoma pancreas No prior abdominal radiation therapy Surgery : See Disease Characteristics No prior surgery carcinoma pancreas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>